Literature DB >> 2425159

Monotherapy with nifedipine for essential hypertension in adult blacks.

M O Fadayomi, K K Akinroye, R O Ajao, L A Awosika.   

Abstract

Thirty-two adult Nigerians with mild-to-moderate essential hypertension were included in a double-blind placebo-controlled trial matching nifedipine 20 mg twice daily with placebo for 6 weeks. Nifedipine caused very significant reductions of both systolic and diastolic blood pressures in all patients. Blood pressure fell from a mean of 181.3 (SE 3.9)/114.7 (SE 2.4) to 122.8 (SE 1.9)/79.4 (SE 1.6). Mean arterial pressure fell from a mean of 136.75 (SE -2.2) to 94.19 (SE -1.39). Polyuria was a common side effect in six of the 16 patients who received nifedipine. One additional patient developed transient occipital headache. Nifedipine monotherapy would appear to be an effective first-line drug in the management of essential hypertension in adult blacks.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425159     DOI: 10.1097/00005344-198605000-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

1.  Enalapril and hydrochlorothiazide in hypertensive Africans.

Authors:  A A Ajayi; E A Oyewo; G O Ladipo; A Akinsola
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 2.  Treatment of hypertension in black patients with angiotensin-converting enzyme inhibitors.

Authors:  N B Shulman
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

Review 3.  The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks.

Authors:  J R M'Buyamba-Kabangu; M Tambwe
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

Review 4.  Calcium channel antagonists. Part III: Use and comparative efficacy in hypertension and supraventricular arrhythmias. Minor indications.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

5.  The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.

Authors:  A A Ajayi; A O Akintomide
Journal:  J Natl Med Assoc       Date:  1995-07       Impact factor: 1.798

6.  Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes.

Authors:  Daniel C Nwachukwu; Anthonius A Eze; Nkiru Z Nwachukwu; Eddy I Aneke; Polycarp U Agu; Nkiru C Azubike; Leonard Fo Obika; Onochie I Okoye
Journal:  Malawi Med J       Date:  2017-06       Impact factor: 0.875

7.  Nocturia as an Unrecognized Symptom of Uncontrolled Hypertension in Black Men Aged 35 to 49 Years.

Authors:  Ronald G Victor; Ning Li; Ciantel A Blyler; O'Neil R Mason; L Cindy Chang; Norma Priscilla B Moy; Mohammad A Rashid; Jeffrey P Weiss; Joel Handler; Jeffrey W Brettler; Michael B Sagisi; Florian Rader; Robert M Elashoff
Journal:  J Am Heart Assoc       Date:  2019-03-05       Impact factor: 5.501

Review 8.  Systematic review: antihypertensive drug therapy in patients of African and South Asian ethnicity.

Authors:  Lizzy M Brewster; Gert A van Montfrans; Glenn P Oehlers; Yackoob K Seedat
Journal:  Intern Emerg Med       Date:  2016-03-30       Impact factor: 3.397

9.  Comparative effectiveness of antihypertensive drugs prescribed in Ethiopian healthcare practice: A pilot prospective, randomized, open label study.

Authors:  Hayelom Gebrekirstos Mengesha; Abraha Hailu Welegerima; Abera Hadgu; Haftom Temesgen; Mala George Otieno; Kiflom Tsegay; Tedros Fisseha; Samuel Getachew; Zekarias Merha; Helen Tewodros; Jiksa Dabessa; Berhane Gebreegzabher; Pammla Petrucka
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.240

10.  Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis.

Authors:  Anna Seeley; Josephine Prynn; Rachel Perera; Rebecca Street; Daniel Davis; Anthony O Etyang
Journal:  BMC Med       Date:  2020-03-27       Impact factor: 8.775

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.